Insider · CIK 0001437911
Neil K Warma
Files at PMN (ProMIS Neurosciences Inc.). First filing -, latest -.
Neil K Warma files SEC Form 4 as CEO and director at PMN (ProMIS Neurosciences Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Neil K Warma has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | PMN ProMIS Neurosciences Inc. | AGrant or award Option (right to buy)derivative | +160,000 | $0.00 | $0 | 160,000 | May 22, 2026 |
| Feb 3, 2026 | PMN ProMIS Neurosciences Inc. | AGrant or award Common Shares | +6,183 | $12.13 | $75k | 6,183 | Feb 5, 2026 |
| Feb 3, 2026 | PMN ProMIS Neurosciences Inc. | AGrant or award Warrants to purchase Common Sharesderivative | +6,183 | - | - | 6,183 | Feb 5, 2026 |
| Sep 22, 2025 | PMN ProMIS Neurosciences Inc. | AGrant or award Option (right to buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Sep 24, 2025 |
Questions about Neil K Warma
Answered from the filings on this page, as of the latest one.
Is Neil K Warma buying or selling?
Neil K Warma has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Neil K Warma's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Neil K Warma has 0.
Where does Neil K Warma file Form 4?
Neil K Warma has filed Form 4 at PMN (ProMIS Neurosciences Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.